News & Updates

Drug discovery quantum computing project receives £6.85m grant

12/02/2021

A consortium of quantum computing companies including Medicines Discovery Catapult (MDC) has secured a £6.85 million grant for a project that is looking to improve drug discovery in cancer. Excerpt from the Press Release: The consortium is being led by SEEQC and will look to accelerate the use of quantum computing within pharmaceutical research to…

Read More

CN BIO and iiCON collaborate to validate novel Covid-19 research tools

12/02/2021

The Infection Innovation Consortium (iiCON) and organ-on-a-chip company (OOC) CN BIO have launched a research collaboration to validate the next generation of Covid-19 research tools. Excerpt from the Press Release: Led by the Liverpool School of Tropical Medicine (LSTM) iiCON is a £174 million programme that brings together industry, academia, and clinicals to accelerate the…

Read More

Chemotherapy may affect muscle cells at lower doses than previously thought

12/01/2021

The cancer therapy may also affect the protein building process, not just cause muscles to degrade Date:November 18, 2021 Source:Penn State Summary:Previous research has found that chemotherapy can trigger muscle loss in people living with cancer, but a new study out of found it may also affect the way the body builds new muscle —…

Read More

Plant-derived antiviral is effective in blocking highly infectious SARS-CoV-2 Delta variant, say scientists

12/01/2021

Date:November 19, 2021 Source:University of Nottingham Summary:A plant-based antiviral has been found to be just as effective at treating all variants of the virus SARS-CoV-2, even the highly infectious Delta variant. Excerpt from the Press Release: A plant-based antiviral, recently discovered by scientists at the University of Nottingham, has been found to be just as…

Read More

A stealthy way to combat tumors

12/01/2021

Biologists show that helper immune cells disguised as cancer cells can help rejuvenate T cells that attack tumors Date:November 19, 2021 Source:Massachusetts Institute of Technology Summary:Researchers uncovered a new way to indirectly activate T cells that can target tumors, by recruiting a population of helper immune cells called dendritic cells. Excerpt from the Press Release:…

Read More

Canada gives full approval to J&J’s single-shot COVID-19 vaccine

11/30/2021

Excerpt from the Press Release: Nov 24 (Reuters) – Johnson & Johnson (JNJ.N) said on Wednesday Canada gave full approval to its single-shot COVID-19 vaccine for people aged 18 years and older, making it the first full approval for the vaccine globally. The vaccine was previously authorised by the country under an interim order. (https://refini.tv/30Zd5TR) Canada, which…

Read More

A different type of COVID-19 vaccine is about to roll out around the world

11/30/2021

Excerpt from the Press Release: Whatever happened to Novavax and Sanofi’s COVID-19 vaccines? Many people thought at the beginning of the pandemic that these were the two most likely vaccines to succeed. AUDIE CORNISH, HOST: A new kind of COVID-19 vaccine is about to roll out around the world. It’s called a protein subunit vaccine.…

Read More

UK data shows good safety of COVID-19 vaccines in pregnancy

11/30/2021

Excerpt from the Press Release: COVID-19 vaccination is safe for pregnant women and not associated with higher rates of complications, data released by the UK Health Security Agency showed on Thursday, as officials urged pregnant women to take up the offer of shots. The real-world data from the rollout of COVID-19 vaccines in Britain support other studies around the…

Read More

BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa

11/29/2021

BioNTech is testing its COVID vaccine against a rapidly spreading variant, the Financial Times said. The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel. Excerpt from the Press Release: BioNTech said it’s testing the COVID-19 vaccine it developed with Pfizer against the new variant that appears to have emerged in southern Africa, and that it would know in two weeks…

Read More

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

11/29/2021

Excerpt from the Press Release: KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives